GSK Abandons Plans For Anemia Drug Launch In Europe
Looking To Avoid Mistakes Of The Past
Executive Summary
GSK is cutting its losses by not launching its anemia drug daprodustat in Europe, something it hopes will make sense to investors who want to see it avoid the underwhelming ‘me too’ launches of the past.